Family facts
IDVParent PIIDHHSN261201500003I
AgencyNih Nci
Awarding officeNih Nci
Awarding agencyDepartment of Health and Human Services (HHS)
Period endAug 29, 2029
IDV obligated$104.0M
Child awards51
Bonuses end Sept 30
Want the durability read on HHSN261201500003I? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Places of performance
StatesMD
Distinctive task orders
1275N91018F00073 — PDX PANELS FROM COMMON TUMORS
Leidos Biomedical Research, Inc. · $67.9M · PoP Sep 25, 2027
75N91018F00071 — HHSN261201500003I; HHSN26100071; 400.021.0071.0001; NCI CBIIT; APPROPRIATED; EXPAND DATA COMMONS; 09/14/18-09/13/23
Leidos Biomedical Research, Inc. · $67.0M · PoP Aug 31, 2027
75N91018F00059 — EBOLA VIRUS AND OTHER INFECTIOUS DISEASES
Leidos Biomedical Research, Inc. · $64.9M · PoP Sep 21, 2028
HHSN26100030 — RESEARCH, DEVELOPMENT, MANUFACTURE OF CLINICAL MATERIALS, AND CLINICAL TESTING OF VACCINES TO PROTECT AGAINST ZIKA VIRUS
Leidos Biomedical Research, Inc. · $63.7M · PoP Sep 21, 2021
75N91018F00079 — HHSN261201500003I; HHSN26100079; 400.001.0079.0001; NCI OD-FREDERICK; ROYALTY; B539 PHASE 2 REFURBISHMENT; 9/24/2018-9/…
Leidos Biomedical Research, Inc. · $58.1M · PoP Aug 25, 2023
75N91018F00077 — CELL-BASED IMMUNOTHERAPY PRODUCTS
Leidos Biomedical Research, Inc. · $53.5M · PoP Aug 29, 2029
HHSN26100033 — EBOLA VIRUS AND OTHER EMERGING AND RE-EMERGING INFECTIOUS DISEASES
Leidos Biomedical Research, Inc. · $44.4M · PoP Sep 25, 2021
HHSN26100043 — EBOLA VIRUS AND OTHER EMERGING & RE-EMERGING INFECTIOUS DISEASES
Leidos Biomedical Research, Inc. · $43.1M · PoP Sep 28, 2022
HHSN26100054 — A NATIONAL CLINICAL LABORATORY NETWORK FOR NCI PRECISION ONCOLOGY
Leidos Biomedical Research, Inc. · $38.5M · PoP Sep 20, 2022
HHSN26100042 — BIOBANK (MOONSHOT)
Leidos Biomedical Research, Inc. · $27.7M · PoP Sep 30, 2025
HHSN26100019 — RESEARCH, DEVELOPMENT, PRODUCTION AND SUPPORT FOR CLINICAL TRIALS BROADLY NEUTRALIZING MONOCLONAL ANTIBODIES (BNMABS)
Leidos Biomedical Research, Inc. · $27.5M · PoP Sep 18, 2021
75N91018F00067 — ADVANCE VACCINE PLATFORMS FOR UNIVERSAL INFLUENZA VACCINE
Leidos Biomedical Research, Inc. · $27.1M · PoP Sep 29, 2023
Want the durability read on HHSN261201500003I? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
Get the free Exposure Check
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.
Data as of · refreshed monthly